Latakia

Primary frontal hyperhidrosis is a chronic condition causing excessive sweating specifically in the forehead area, which can greatly impact a person's social life and daily activities. This research aims to assess the safety and effectiveness of Botulinum Toxin Type A injections for treating this condition. The study uses clinical tests and patient feedback to evaluate improvements in sweating and satisfaction one month after treatment. The treatment involves mapping the forehead to identify sweating areas using Minor's iodine-starch test. Botulinum toxin type A is prepared at a concentration of 20 units per milliliter, and small doses of 2 units are injected at spaced points within the affected area. The total dose ranges from 40 to 80 units depending on the size of the sweating region. Participants receive a single treatment session with follow-up one month later. Participants will be evaluated at the start and one month after treatment using the Hyperhidrosis Disease Severity Scale and Minor's iodine-starch test to measure changes in sweating. Patient satisfaction is recorded using a questionnaire, and any side effects are monitored. The study requires participants to be between 18 and 40 years old and tracks both clinical and patient-reported outcomes over this period.

Researchers are evaluating the effectiveness and pain response of two local anesthesia methods in children undergoing dental treatment using an electronic syringe. This study focuses on comparing ligament anesthesia and inferior alveolar nerve block (IANB) techniques applied during pulpectomy procedures on two different teeth in the same child across two visits. The research aims to understand how computerized syringes, which control anesthetic flow and include features like music and auditory cues to reduce fear, impact the child's comfort during dental care. The study uses an electronic syringe device to deliver local anesthesia with two techniques: the periodontal ligament (intraligament) method and the inferior alveolar nerve block (IANB) method. Each child receives each anesthesia technique on separate visits for different teeth. The syringe offers precise control of injection speed and provides audible feedback on anesthetic delivery, with options for rapid, slow, or ligament injections to improve comfort and efficiency. Participants will be monitored for pain intensity at three treatment stages: during anesthesia injection, rubber dam placement, and pulp chamber opening. After the procedure, pain will be assessed using age-appropriate scales, and satisfaction levels of both children and parents regarding the electronic syringe use will be recorded. The main outcome measured is the success rate of the electronic syringe anesthesia during the dental procedures from anesthesia start until pulp chamber opening, helping to evaluate the comfort and effectiveness of each technique.

Researchers are evaluating the aesthetic effectiveness of resin infiltration treatment with or without the use of sodium hypochlorite on opacities caused by Molar Incisor Hypomineralisation (MIH) in permanent incisors. The study also compares parents' satisfaction with the results of the two different application methods. Participants will have teeth diagnosed with MIH-related opacities based on established diagnostic criteria. The study involves two groups: a test group and a control group. In the test group, sodium hypochlorite 5.25% is applied using a cotton wad before treatment and as an irrigation step after the first and second etching cycles. Both groups receive etching cycles using ICON®-Etch and ICON®-Dry materials, followed by application of ICON®-Infiltrant after the third etching cycle. The control group follows the same protocol but without sodium hypochlorite use. Participants' teeth will be evaluated for masking effectiveness using color difference measurements between the opacity and adjacent enamel. The infiltration proportion of the opacity will be quantified as a percentage of the infiltrated area. Parents' satisfaction with the treatment outcomes will be assessed using a Likert scale. Masking efficacy will be analyzed on day 1 and again 7 to 10 days later.

Researchers are evaluating the effectiveness of ursodeoxycholic acid (UDCA) as an add-on treatment to continuous triple phototherapy for managing indirect hyperbilirubinemia in newborns who are at least 34 weeks gestational age. This prospective, open-label, randomized controlled trial aims to see if UDCA can help reduce the time and level of bilirubin in the blood more quickly compared to phototherapy alone. The study carefully balances groups based on the type of jaundice, including hemolytic, non-hemolytic, and G6PD deficiency. Participants are randomly assigned to one of two groups: one group receives continuous triple phototherapy alone, while the other group receives the same phototherapy combined with oral UDCA at a dose of 10 mg/kg per day divided into two doses. The UDCA is given with feeds until bilirubin levels drop below the threshold that requires treatment as per American Academy of Pediatrics guidelines. The treatment and monitoring follow a strict protocol, and randomization ensures balance across different types of jaundice. During the study, blood bilirubin levels are measured every 12 hours to monitor the reduction until discharge. Researchers are primarily measuring how quickly and how much the total serum bilirubin decreases below phototherapy thresholds within the first 7 days, including the mean reduction at 12 hours. The study also tracks the need for additional therapy and subgroup responses. The total participation time depends on bilirubin levels but includes close monitoring throughout the treatment period.